THERE ARE WAYS TO SAVE ON BREZTI UNTIL A GENERIC IS AVAILABLE
KEY TAKEAWAYS
There is currently no generic version of Breztri Aerosphere available as of 2026.
Patent protections for Breztri Aerosphere may extend into 2038, which could delay the availability of lower-cost generic alternatives until those protections expire and manufacturers are able to develop and approve equivalent products.
While a generic option is not available, patients may have access to insurance coverage, manufacturer savings programs, and other cost-assistance options that may help reduce out-of-pocket expenses. In some cases, eligible patients may be able to lower their cost to $0 through available savings programs.
Breztri Aerosphere is a brand-name prescription inhaler that contains three active ingredients: budesonide, glycopyrrolate, and formoterol fumarate.
This triple-combination inhaler therapy is approved by the U.S. Food and Drug Administration (FDA) for:
- Long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults
- Treatment of asthma in adults and children ages 12 and older
Because Breztri Aerosphere is a brand-name medication, its cost can be high. A single inhaler may cost more than $900 at retail price without insurance, leading many patients to look for a lower-cost generic alternative.
Currently, no generic version of Breztri Aerosphere is available. This article explores what Breztri is, how the inhaler works, why a generic option has not yet become available, its cost, and potential ways patients may reduce their out-of-pocket expenses.
Is there a generic for Breztri?
No, there is currently no FDA-approved generic version of Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) available.
Because Breztri Aerosphere is brand-name only, pharmacists cannot substitute it with a lower-cost generic equivalent when filling a prescription. Unlike medications with approved generics, there is currently no FDA-approved alternative that contains the same active ingredients in the same inhaler formulation.
This means the cost at the pharmacy may remain high, making it important for patients to explore available savings options, including:
- Insurance coverage options
- Manufacturer savings programs
- Prescription discount programs
- Assistance programs for eligible patients
These options may help reduce out-of-pocket costs for people who need Breztri Aerosphere for long-term COPD or asthma management.
What is Breztri Aerosphere?
Breztri Aerosphere is a fixed-dose triple combination inhaler manufactured by AstraZeneca. It was first approved by the FDA in 2020 as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults. In April 2026, the FDA expanded its approval to include maintenance treatment of asthma in adults and children ages 12 years and older.
Breztri Aerosphere is a maintenance inhaler, meaning it is taken regularly to help control symptoms over time. It is not a rescue inhaler for sudden breathing problems.
For COPD, the recommended dose is typically:
- Two inhalations twice daily (morning and evening)
According to James Lyons, MD, Breztri is designed for daily symptom control rather than immediate relief during an asthma or COPD flare-up.
How Breztri Aerosphere Works
Breztri contains three active ingredients from three different medication classes:
Budesonide
An inhaled corticosteroid (ICS) that reduces airway inflammation by decreasing immune activity and inflammatory signals in the lungs.Glycopyrrolate
A long-acting muscarinic antagonist (LAMA), also known as an anticholinergic medication. It helps relax airway muscles by blocking muscarinic receptors, allowing the airways to open (bronchodilation).Formoterol fumarate
A long-acting beta2-agonist (LABA) that stimulates beta2 receptors to relax airway muscles and improve airflow.
Together, these three medications provide triple therapy, targeting multiple causes of airway narrowing:
- Reducing inflammation
- Relaxing airway muscles through the muscarinic pathway
- Relaxing airway muscles through the beta2 pathway
Triple Therapy for COPD
Breztri Aerosphere is one of two FDA-approved fixed-dose triple therapy inhalers available in the U.S. for COPD. The other is:
- Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), manufactured by GlaxoSmithKline
While both are triple therapy inhalers, they use different active ingredients and dosing schedules:
- Breztri Aerosphere: Taken twice daily
- Trelegy Ellipta: Taken once daily
Who May Need Triple Therapy?
Triple therapy is not necessary for everyone with COPD or asthma. Healthcare providers consider factors such as:
- High blood eosinophil levels (more than 300 cells/µL)
- Severe airflow limitation
- Frequent COPD exacerbations despite appropriate medication use
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines recommend considering triple therapy for certain patients who continue to experience symptoms or exacerbations despite other treatments.
A healthcare provider can determine whether Breztri Aerosphere is appropriate based on a person’s diagnosis, symptoms, lung function, medical history, and response to current therapies.
Why doesn’t Breztri have a generic yet?
Breztri Aerosphere does not currently have a generic version because active patents and exclusivity protections are still in place, which can prevent other manufacturers from producing an FDA-approved generic equivalent.
When a pharmaceutical company develops a new medication, it may receive patent protection that typically prevents generic competition for a period of time. Patent timelines can vary because they may be extended or shortened depending on regulatory, medical, and legal factors.
As of 2026, Breztri Aerosphere has active patents that are expected to expire in the coming years, with some protections extending into approximately 2030 and beyond. Once relevant patents expire, other manufacturers may apply to the FDA to produce a generic version.
However, creating a generic version of an inhaler can be more complicated than making a generic pill. For combination inhalers like Breztri Aerosphere, manufacturers must develop a product that matches:
- The same active ingredients:
- Budesonide
- Glycopyrrolate
- Formoterol fumarate
- The same dosage strength
- The same therapeutic effect
- A comparable inhaler delivery system
The inhaler device itself may also have patent protection, adding another layer of complexity. Because manufacturers must develop and test both the medication formulation and the delivery system, generic triple-therapy inhalers may take longer to reach the market compared with simpler generic medications.
How much does Breztri cost without a generic?
The cost of Breztri Aerosphere can vary significantly depending on insurance coverage, pharmacy pricing, and available savings programs.
The average retail price for one Breztri Aerosphere inhaler (10.7 g, 160-9-4.8 mcg/act)—which is typically about a one-month supply—is around $936 without insurance.
However, the actual out-of-pocket cost may be lower depending on available discounts. For example, eligible patients may pay as little as $572 with a SingleCare discount at participating pharmacies.
Insurance Coverage for Breztri Aerosphere
Many insurance plans cover Breztri Aerosphere for COPD treatment, including some:
- Medicare plans
- Medicaid plans
- Commercial insurance plans
However, some insurance providers may require:
- Prior authorization — approval from the insurance company before coverage begins
- Step therapy — trying other medications first before approving Breztri
According to AstraZeneca, average out-of-pocket costs may vary by insurance type:
- Commercial insurance: Around $44 per month
- Medicare Part D: Around $45 per month
- Medicaid: Around $1 per month
Because coverage and pricing vary, patients may benefit from comparing insurance coverage, pharmacy prices, and available savings programs before filling a prescription.
BREZTRI AEROSPHERE COST AT A GLANCE
| Scenario | Estimated Cost |
|---|---|
| Retail cash price (no insurance, no coupon) | $936 for 1 Breztri Aerosphere 10.7 g inhaler (160-9-4.8 mcg/act) |
| With a SingleCare coupon | $572 for 1 Breztri Aerosphere 10.7 g inhaler (160-9-4.8 mcg/act) |
| With commercial insurance (average copay) | $44 per month |
| With Medicare Part D (average copay) | $45 per month |
Note: Actual out-of-pocket costs may vary depending on the pharmacy, insurance plan, eligibility for savings programs, and coverage requirements such as prior authorization or step therapy.
How to afford Breztri without a generic
Although there is no generic version of Breztri Aerosphere available yet, there are still several ways patients may be able to reduce their out-of-pocket costs.
Savings options may include:
- Manufacturer savings programs, which may lower costs for eligible patients and, in some cases, reduce out-of-pocket costs to $0
- Insurance coverage support, including help with prior authorization requirements
- Formulary alternatives, when appropriate and recommended by a healthcare provider
- Patient assistance programs or financial support foundations for qualifying individuals
“Patients frequently discontinue their prescribed treatment because of cost,” says Dr. Hoedebecke. Cost barriers can make it difficult for some people to continue medications they need, but healthcare professionals can help patients explore available resources.
Providers may assist by helping patients:
- Complete prior authorization paperwork
- Identify covered medication options
- Access manufacturer savings programs
- Find financial assistance programs that fit their situation
If medication cost becomes a concern, patients should discuss options with their healthcare provider or pharmacist before stopping treatment.
Consider the following options to save on Breztri:
Although a generic version of Breztri Aerosphere is not available yet, there are several options that may help reduce prescription costs.
1. Use a SingleCare coupon for Breztri
A SingleCare coupon or discount card may lower the cost of Breztri Aerosphere at participating pharmacies without using insurance. These coupons are free and may be accepted at many retail pharmacies, including:
- Kroger
- CVS Pharmacy
- Other participating pharmacies
Patients can compare available pharmacy prices through the SingleCare Breztri page to find potential savings.
2. Check eligibility for manufacturer savings programs
AstraZeneca offers savings programs that may help eligible patients reduce their Breztri costs.
Breztri Zero Pay Program
- Available for people with commercial or private insurance
- May reduce eligible patients’ out-of-pocket cost to $0
- Eligibility requirements may include:
- Age 18 or older
- A prescription for Breztri
- Insurance coverage for Breztri without certain restrictions, such as step therapy or prior authorization requirements
- Not being enrolled in government-funded insurance programs such as Medicare or Medicaid
- Additional restrictions and maximum savings limits may apply
AZ&Me Prescription Savings Program
- Designed to help eligible patients who:
- Do not have insurance, or
- Have Medicare but still cannot afford their medication
- Eligible patients may receive Breztri at no cost for a period of time
- Income requirements may apply, including household income limits based on the Federal Poverty Level (FPL)
3. Talk with your healthcare provider about prior authorization and appeals
If insurance denies coverage for Breztri, patients may have options to appeal the decision.
Healthcare providers may support coverage requests by providing documentation such as:
- Pulmonary function test results
- Medical history
- Records of previous inhalers tried
- Explanation of why Breztri is medically appropriate
This information may help insurers reconsider coverage decisions.
4. Ask about alternative triple-therapy options
If Breztri Aerosphere is too expensive or not covered, a healthcare provider may discuss other treatment options, including other triple-combination inhalers such as Trelegy Ellipta.
While Trelegy Ellipta is also a brand-name medication, it may have different insurance coverage depending on the patient’s plan.
Patients should talk with their healthcare provider before switching medications to determine which option is appropriate for their condition.
Expert takeaway
There may not be a generic version of Breztri for 4 years or more. Consider how you can obtain Breztri at a lower cost if you and your physician agree this is the appropriate medicine for you,” says Leslie Greenberg, MD, Associate Professor of Community and Family Medicine at the University of Nevada, Reno School of Medicine.
Because a generic alternative is not currently available, patients who are prescribed Breztri Aerosphere may need to explore other ways to manage costs, such as:
- Reviewing insurance coverage and formulary options
- Checking eligibility for manufacturer savings programs
- Using prescription discount programs
- Discussing affordable alternatives with a healthcare provider when appropriate
The best option depends on the individual’s medical needs, insurance coverage, and financial situation. Patients should speak with their healthcare provider before making changes to their prescribed treatment.
Frequently asked questions
When will a Breztri generic be available?
Because patent protections can prevent other manufacturers from producing FDA-approved generic equivalents, the availability of a lower-cost generic alternative will depend on when these protections expire and when manufacturers can successfully develop and receive approval for an equivalent inhaler product.
Is Breztri covered by Medicare?
Some plans may require additional steps before approving coverage, such as:
- Prior authorization: The insurance plan requires approval before covering Breztri.
- Step therapy: The patient may need to try other preferred medications first before the plan will cover Breztri.
Patients should check with their Medicare plan or healthcare provider to understand coverage requirements and available cost-saving options.
What inhaler is similar to Breztri?
The only other FDA-approved triple-therapy combination inhaler currently available in the U.S. is Trelegy Ellipta.
Like Breztri Aerosphere, Trelegy Ellipta is a triple therapy inhaler that combines three medication classes to help manage respiratory conditions. However, it contains different active ingredients and uses a different inhaler device.
The choice between Breztri Aerosphere and Trelegy Ellipta depends on factors such as:
- The patient’s diagnosis and symptoms
- Response to current treatment
- Insurance coverage and formulary preferences
- Healthcare provider recommendations
The SingleCare prices in this article are the most accurate at the time of publishing in ZIP code 23666 as of Aug. 4, 2026. Prices vary by pharmacy. Visit the coupon page for updated prescription prices at pharmacies near you.
Source: SingleCare